Organisation paid for research Program year 2022 Source: CMS Open Payments

Columbus Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$658,725

52 payments

Through program year 2022, Columbus Clinical Research is reported as receiving $658,725 in research payments, across 52 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $19,091 4
2021 Research $395 1
2020 Research $143,155 12
2019 Research $496,084 35

Breakdown

Who paid Research payments · program years 2019–2022
  1. Allergan Inc. $589,192 45 payments
  2. AstraZeneca Pharmaceuticals LP $53,245 6 payments
  3. AstraZeneca UK Limited $16,288 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. A Phase 1b Double-Blind, Placebo-Controlled, Randomized Study of the Biomarker Response After Single and Multiple Doses of Relamorelin in Participants with Diabetes Mellitus Type I, Diabetes Mellitus Type II, and Healthy Participants $248,041 16 payments
  2. PH 3 Pivotal LCL and GL and LCL - Useu $198,981 13 payments
  3. Glabellar Lines Only $69,285 4 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $64,267 4 payments
  5. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $49,990 2 payments
  6. A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease $18,736 2 payments
  7. 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $4,044 5 payments
  8. A 46-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Longterm Study With A 6-Week Randomized-Withdrawal Period to Evaluate the Safety and $3,230 1 payment
  9. A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis $950 1 payment
  10. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $452 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record